A Multicenter, Randomized, Single-Blind Crossover Study of the Safety and Tolerability of Two Adalimumab Formulations in Adult Subjects With Rheumatoid Arthritis.
Phase of Trial: Phase II
Latest Information Update: 16 Jun 2018
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors AbbVie
- 16 Jun 2018 Results pain perception after injection of both ABP formulation by taking data form this and other 3 studies, presented at the 19th Annual Congress of the European League Against Rheumatism.
- 01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 26 Sep 2012 Planned End Date changed from 1 Jun 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.